LivaNova PLC has successfully concluded the CORE-VNS study, reinforcing the substantial impact of VNS Therapy™ on individuals suffering from severe focal seizures due to drug-resistant epilepsy (DRE). This extensive research encompassed over 800 participants globally, highlighting significant improvements in both children and adults over a 36-month period.
Study Highlights and Results
The CORE-VNS study, now complete with its final clinical report, underscores the therapy’s efficacy in reducing seizures. Remarkably, children aged 4 to 18 experienced an 87% median reduction in FIA motor seizures after three years. Adults reported an 80% median decrease, with 34% achieving complete seizure freedom for three months preceding their final study visit. Additionally, focal to bilateral tonic-clonic seizures saw a median reduction of 100% in children and 95% in adults, demonstrating the therapy’s broad applicability and effectiveness across age groups.
Implications and Future Directions
The early onset of seizure reduction observed at the three-month mark indicates that VNS Therapy provides prompt relief, which continues to improve over time. With an impressive 82% patient retention rate, the study also highlights the therapy’s tolerability and sustained patient engagement. These findings position VNS Therapy as a vital option for those struggling with conventional treatments for epilepsy.
– High retention rate signifies strong patient commitment and therapy acceptance.
– Significant seizure reductions validate VNS Therapy’s effectiveness across diverse patient demographics.
– Rapid initial response suggests potential for swift quality of life improvements.
The CORE-VNS study stands as the largest of its kind, offering comprehensive insights into VNS Therapy’s role in managing drug-resistant epilepsy. These robust results not only support current therapeutic approaches but also pave the way for broader adoption and integration into epilepsy treatment protocols worldwide.
VNS Therapy’s non-invasive nature and outpatient procedure make it an accessible option compared to other surgical interventions. Patients and healthcare providers can consider this therapy as a viable long-term solution to control severe seizures, potentially reducing the reliance on multiple medications and improving overall patient outcomes. As awareness and accessibility of VNS Therapy increase, it holds promise for significantly enhancing the quality of life for those battling drug-resistant epilepsy.
This article has been prepared with the assistance of AI and reviewed by an editor. For more details, please refer to our Terms and Conditions. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author.
